Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Standardized definitions of molecular response in chronic myeloid leukemia

Abstract

The International Randomized Study of Interferon and STI571 (IRIS) demonstrated long-term cytogenetic responses in patients with chronic-phase chronic myeloid leukemia (CML-CP) treated with the tyrosine kinase inhibitor (TKI) imatinib. However, deep molecular responses (MRs), as measured by reductions in BCR-ABL transcript levels below the threshold of major MR, were achieved only by a small proportion of patients. With the advent of the second-generation TKIs nilotinib and dasatinib for the treatment of patients with newly diagnosed CML-CP, the proportion of patients who achieve the deepest levels of MR is likely to increase significantly. With these changes, the potential for patient eligibility in TKI cessations studies is becoming a more widely discussed topic and area for research. These developments highlight the need for robust, standardized and workable definitions of deep MRs. Specifically, it is critical that the measurement of MR is standardized in a manner to withstand both intra- and inter-laboratory variability, as well as new methodological developments. This review summarizes the relevant clinical background and proposes a framework within which standardization of MR can be taken forward.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1

References

  1. Deininger M, O’Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009; 114: 462 (abstract 1126).

    Google Scholar 

  2. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423–1432.

    CAS  Article  PubMed  Google Scholar 

  3. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28–37.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041–6051.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  5. Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 2009; 114: 4933–4938.

    CAS  Article  PubMed  Google Scholar 

  6. Cortes JE, Jones D, O’Brien S, Jabbour E, Konopleva M, Ferrajoli A et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010; 28: 392–397.

    CAS  Article  PubMed  Google Scholar 

  7. Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010; 28: 398–404.

    CAS  Article  PubMed  Google Scholar 

  8. Radich JP, Kopecky KJ, Kamel-Reid S, Stock W, Paietta E, Wadleigh M et al. A randomized phase II trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): the S0325 Intergroup trial. Blood 2010, 116 (abstract LBA-6).

  9. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251–2259.

    CAS  Article  PubMed  Google Scholar 

  10. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260–2270.

    CAS  Article  PubMed  Google Scholar 

  11. Hughes TP, Hochhaus A, Saglio G, Kim DW, Jootar S, le Coutre PD et al. ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). Blood 2010; 116: 94–95, (abstract 0207).

    Article  Google Scholar 

  12. Hochhaus A, Lobo C, Pasquini R, Clark R, Kim DW, Issaragrisil S et al. Continued superiority of nilotinib vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond 1 year. Haematologica 2010; 95: 459 (abstract 1113).

    Google Scholar 

  13. Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011; 12: 841–851.

    CAS  Article  PubMed  Google Scholar 

  14. Gugliotta G, Castagnetti F, Breccia M, Levato L, Capucci A, Tiribelli M et al. Early CP CML, Nilotinib 400 mg Twice Daily Frontline: Beyond 3 Years, Results Remain Excellent and Stable (A GIMEMA CML Working Party Trial). Blood 2011; 116, abstract 2756.

  15. Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS et al. Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012; 119: 1123–1129.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  16. Kantarjian HM, Baccarani M, Jabbour E, Saglio G, Cortes JE . Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy. Clin Cancer Res 2011; 17: 1674–1683.

    CAS  Article  PubMed  Google Scholar 

  17. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319–325.

    CAS  Article  PubMed  Google Scholar 

  18. Cortes J, O’Brien S, Kantarjian H . Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004; 104: 2204–2205.

    CAS  Article  PubMed  Google Scholar 

  19. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029–1035.

    CAS  Article  PubMed  Google Scholar 

  20. Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Bartley PA et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010; 10: 1719–1724.

    Article  Google Scholar 

  21. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041–2050.

    CAS  PubMed  Google Scholar 

  22. Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 2000; 95: 62–66.

    CAS  PubMed  Google Scholar 

  23. Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001; 98: 3074–3081.

    CAS  Article  PubMed  Google Scholar 

  24. Kantarjian HM, O’Brien S, Cortes JE, Shan J, Giles FJ, Rios MB et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003; 97: 1033–1041.

    CAS  Article  PubMed  Google Scholar 

  25. Burchert A, Müller MC, Kostrewa P, Erben P, Bostel T, Liebler S et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 2010; 28: 1429–1435.

    CAS  Article  PubMed  Google Scholar 

  26. Zhang B, Irvine D, Ho YW, Buonamici S, Manley P, Holyoake TL et al. Inhibition of chronic myeloid leukemia stem cells by the combination of the hedgehog pathway inhibitor LDE225 with nilotinib. Blood 2010; 116: 227 (abstract 514).

    Google Scholar 

  27. Nair RR, Tolentino JH, Argilagos RF, Zhang L, Pinilla-Ibarz J, Hazlehurst LA . Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML. Leuk Res 2012; 36: 756–763.

    CAS  Article  PubMed  Google Scholar 

  28. Packer LM, Rana S, Hayward R, O’Hare T, Eide CA, Rebocho A et al. Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell 2011; 20: 715–727.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  29. Kumari A, Brendel C, Hochhaus A, Neubauer A, Burchert A . Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood 2012; 119: 530–539.

    CAS  Article  PubMed  Google Scholar 

  30. Zhang JG, Lin F, Chase A, Goldman JM, Cross NC . Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation. Blood 1996; 87: 2588–2593.

    CAS  PubMed  Google Scholar 

  31. Sobrinho-Simoes M, Wilczek V, Score J, Cross NC, Apperley JF, Melo JV . In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood 2010; 116: 1329–1335.

    CAS  Article  PubMed  Google Scholar 

  32. Deininger M . Hematology: curing CML with imatinib—a dream come true? Nat Rev Clin Oncol 2011; 8: 127–128.

    CAS  Article  PubMed  Google Scholar 

  33. Hughes TP, Lipton JH, Leber B, Spector N, Cervantes F, Pasquini R et al. Complete molecular response (CMR) rate with nilotinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) without CMR after 2 years on imatinib: preliminary results from the randomized ENESTcmr trial of nilotinib 400 mg twice daily (BID) vs imatinib. Blood 2011; 118: 278 (abstract 606).

    Google Scholar 

  34. Branford S, Fletcher L, Cross NC, Müller MC, Hochhaus A, Kim DW et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008; 112: 3330–3338.

    CAS  Article  PubMed  Google Scholar 

  35. Müller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009; 23: 1957–1963.

    Article  PubMed  Google Scholar 

  36. White HE, Matejtschuk P, Rigsby P, Gabert J, Lin F, Wang YL et al. Establishment of the 1st World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood 2010; 116: e111–e117.

    CAS  Article  PubMed  Google Scholar 

  37. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)—a Europe against cancer program. Leukemia 2003; 17: 2474–2486.

    CAS  Article  PubMed  Google Scholar 

  38. Giles F, Rosti G, Ossenkoppele GJ, Tulliez M, Stentoft J, Giagounidis A et al. A Phase IIIb Multicentre Open-Label Study of Nilotinib in Adult Patients with Newly Diagnosed BCR-ABL Positive Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A European Clinical Initiative with EUTOS Collaboration for Standardisation of Molecular Remission. Blood 2011; 118: 1186–1187, (abstract 2759).

    Google Scholar 

Download references

Acknowledgements

Financial support for editorial assistance in the production of part of this review was provided by Novartis. We thank Michael Mandola, PhD (Articulate Science) for editorial assistance. Research support was received by Novartis Pharma, Switzerland, and the European LeukemiaNet via the ‘European Treatment and Outcome Study’, EUTOS.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A Hochhaus.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cross, N., White, H., Müller, M. et al. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26, 2172–2175 (2012). https://doi.org/10.1038/leu.2012.104

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2012.104

Keywords

  • CML
  • BCR-ABL
  • molecular response

Further reading

Search

Quick links